636 related articles for article (PubMed ID: 9399764)
1. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
2. [Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma].
Folwaczny C; Läritz M; Meurer M; Endres SP; König A; Schindlbeck N
Z Gastroenterol; 1997 Oct; 35(10):905-12. PubMed ID: 9432812
[TBL] [Abstract][Full Text] [Related]
3. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
[TBL] [Abstract][Full Text] [Related]
4. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea.
von der Ohe MR; Camilleri M; Kvols LK; Thomforde GM
N Engl J Med; 1993 Oct; 329(15):1073-8. PubMed ID: 8371728
[TBL] [Abstract][Full Text] [Related]
5. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
7. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.
Soudah HC; Hasler WL; Owyang C
N Engl J Med; 1991 Nov; 325(21):1461-7. PubMed ID: 1944424
[TBL] [Abstract][Full Text] [Related]
8. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis.
Renzi D; Mantellini P; Calabrò A; Panerai C; Amorosi A; Paladini I; Salvadori G; Garcea MR; Surrenti C
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):62-70. PubMed ID: 9615269
[TBL] [Abstract][Full Text] [Related]
9. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors.
Gregersen T; Grønbæk H; Worsøe J; Schlageter V; Laurberg S; Krogh K
Scand J Gastroenterol; 2011 Jul; 46(7-8):895-902. PubMed ID: 21623673
[TBL] [Abstract][Full Text] [Related]
10. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
11. [Effects of the administration of somatostatin 14 in the carcinoid syndrome. Clinical and biological study of 2 cases].
Guillard JF; Galmiche JP; Chayvialle JA; Kremer M; Comoy E; Lerebours E; Charbonnel B; Colin R
Gastroenterol Clin Biol; 1983 Dec; 7(12):1016-22. PubMed ID: 6141119
[TBL] [Abstract][Full Text] [Related]
12. An open trial of octreotide long-acting release in the management of short bowel syndrome.
Nehra V; Camilleri M; Burton D; Oenning L; Kelly DG
Am J Gastroenterol; 2001 May; 96(5):1494-8. PubMed ID: 11374688
[TBL] [Abstract][Full Text] [Related]
13. Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study.
Park MI; Ferber I; Camilleri M; Allenby K; Trillo R; Burton D; Zinsmeister AR
Neurogastroenterol Motil; 2006 Jan; 18(1):28-36. PubMed ID: 16371080
[TBL] [Abstract][Full Text] [Related]
14. Effect of tegaserod on gut transit in male and female subjects.
Degen L; Petrig C; Studer D; Schroller S; Beglinger C
Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
[TBL] [Abstract][Full Text] [Related]
15. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients.
Massimino K; Harrskog O; Pommier S; Pommier R
J Surg Oncol; 2013 Jun; 107(8):842-6. PubMed ID: 23592524
[TBL] [Abstract][Full Text] [Related]
16. Correlation of gut hormones with irritable bowel syndrome.
Zhang H; Yan Y; Shi R; Lin Z; Wang M; Lin L
Digestion; 2008; 78(2-3):72-6. PubMed ID: 18948690
[TBL] [Abstract][Full Text] [Related]
17. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
18. [Role of gut hormones in irritable bowel syndrome].
Morise K; Furusawa A; Yamamoto H; Saito H
Nihon Rinsho; 1992 Nov; 50(11):2697-702. PubMed ID: 1287245
[TBL] [Abstract][Full Text] [Related]
19. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
20. Effect of rectal distension on gallbladder emptying and circulating gut hormones.
van Hoek F; Mollen RM; Hopman WP; Kuijpers HH; Jansen JB
Eur J Clin Invest; 2000 Nov; 30(11):988-94. PubMed ID: 11114961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
